One-third of CLL patients resistant to BTK inhibitors therapy develop RT with a dismal outcome [160] and in this group, SF3B1 mutations are more frequent than BTK mutations [24], the most common ones described in ibrutinib resistant patients [161]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.